Dose study of rosuvastatin calcium in the treatment of coronary heart disease and hyperlipidemia

Dose study of rosuvastatin calcium in the treatment of coronary heart disease and hyperlipidemia

To study the clinical efficacy of different doses of rosuvastatin to treat elderly patients with senile coronary heart disease and hyperlipidemia. By means of retrospective analysis, 150 elderly patients with coronary heart disease and hyperlipidemia who were treated in Zhangjiakou First Hospital fr...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:American journal of translational research 2023-01, Vol.15 (5), p.3403-3409
Hauptverfasser: Zhang, Jihong, Gong, Ying, Peng, Juan, Han, Junling, Li, Fuqiang, Song, Liqin, Qiao, Cuifeng
Format: Artikel
Sprache:eng
Schlagworte:
Original
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 3409
container_issue 5
container_start_page 3403
container_title American journal of translational research
container_volume 15
creator Zhang, Jihong
Gong, Ying
Peng, Juan
Han, Junling
Li, Fuqiang
Song, Liqin
Qiao, Cuifeng
description To study the clinical efficacy of different doses of rosuvastatin to treat elderly patients with senile coronary heart disease and hyperlipidemia. By means of retrospective analysis, 150 elderly patients with coronary heart disease and hyperlipidemia who were treated in Zhangjiakou First Hospital from January 2020 to December 2020 were selected as the study subjects. They were divided into three groups (50 patients in each group) according to the different treatment methods. All patients were given routine treatment for coronary heart disease and hyperlipidemia. At the same time, group A got 5 mg of rosuvastatin calcium per day, group B got 10 mg and group C got C, 20 mg. After 4 months of continuous treatment, changes of blood lipid level, inflammatory factors, and cardiac function in the three groups were compared before and after treatment. Finally, the incidence of adverse reactions in the three groups was statistically compared. After 4 months of treatment, the levels of TC, LDL, and TG in group B were significantly lower than those of group A, and the levels of HDL were significantly higher than those in group A (P0.05). Using 2 months, 3 months, and 4 months of therapy as time points, the blood lipid levels of the B and C groups was lower than in group A (P
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10250966</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2825157202</sourcerecordid><originalsourceid>FETCH-LOGICAL-p197t-f73eb1dd145a9e3980a2ad6c63d8e73f5a98590574090e118f3f26cc4851c81b3</originalsourceid><addsrcrecordid>eNpVkEtPwzAQhCMEoqXwF5CPXCL5ETvOCaHylCpxgXPY2htqlMTBdir13xNEQeW0o93RN6M9yuasKkSuWcGOD_QsO4vxg1IlK8VPs5koBRVKyXn2dusjkphGuyO-IcHHcQsxQXI9MdAaN3ZkkmmDJAWE1GGfvo3GB99D2JENQkjEuogwgaC3ZLMbMLRucBY7B-fZSQNtxIv9XGSv93cvy8d89fzwtLxZ5QOrypQ3pcA1s5YVEioUlabAwSqjhNVYimbaallRWRa0osiYbkTDlTGFlsxothaL7PqHO4zrDq2ZegZo6yG4bqpZe3D1_0vvNvW739aMckkrpSbC1Z4Q_OeIMdWdiwbbFnr0Y6y55pLJklM-WS8Pw_5Sfv8qvgC0c3eA</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2825157202</pqid></control><display><type>article</type><title>Dose study of rosuvastatin calcium in the treatment of coronary heart disease and hyperlipidemia</title><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><creator>Zhang, Jihong ; Gong, Ying ; Peng, Juan ; Han, Junling ; Li, Fuqiang ; Song, Liqin ; Qiao, Cuifeng</creator><creatorcontrib>Zhang, Jihong ; Gong, Ying ; Peng, Juan ; Han, Junling ; Li, Fuqiang ; Song, Liqin ; Qiao, Cuifeng</creatorcontrib><description>To study the clinical efficacy of different doses of rosuvastatin to treat elderly patients with senile coronary heart disease and hyperlipidemia. By means of retrospective analysis, 150 elderly patients with coronary heart disease and hyperlipidemia who were treated in Zhangjiakou First Hospital from January 2020 to December 2020 were selected as the study subjects. They were divided into three groups (50 patients in each group) according to the different treatment methods. All patients were given routine treatment for coronary heart disease and hyperlipidemia. At the same time, group A got 5 mg of rosuvastatin calcium per day, group B got 10 mg and group C got C, 20 mg. After 4 months of continuous treatment, changes of blood lipid level, inflammatory factors, and cardiac function in the three groups were compared before and after treatment. Finally, the incidence of adverse reactions in the three groups was statistically compared. After 4 months of treatment, the levels of TC, LDL, and TG in group B were significantly lower than those of group A, and the levels of HDL were significantly higher than those in group A (P&lt;0.05). There was no significant difference of the above indicators between groups B and C after 4 months of treatment (P&gt;0.05). Using 2 months, 3 months, and 4 months of therapy as time points, the blood lipid levels of the B and C groups was lower than in group A (P&lt;0.05); Serum hs-CRP and TNF of patients in group B and group C after 4 months of treatment were significantly lower than those of group A (P&lt;0.05); The LVEF comparison between groups showed that C was higher than A (P&lt;0.05); The occurrence rate between adverse reactions during the 4 months of medication did not have statistical significance (P&gt;0.05). Rosuvastatin calcium canimprove the clinical symptoms of elderly patients with coronary heart disease complicated by hyperlipidemia, and can improve the blood lipid level, cardiac function and the level of inflammatory factors in the body, but the clinical effect is not significantly improved by increasing the application dose. This suggests that the daily application dose should be 10 mg.</description><identifier>ISSN: 1943-8141</identifier><identifier>EISSN: 1943-8141</identifier><identifier>PMID: 37303665</identifier><language>eng</language><publisher>United States: e-Century Publishing Corporation</publisher><subject>Original</subject><ispartof>American journal of translational research, 2023-01, Vol.15 (5), p.3403-3409</ispartof><rights>AJTR Copyright © 2023.</rights><rights>AJTR Copyright © 2023 2023</rights><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10250966/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10250966/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,723,776,780,881,53766,53768</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/37303665$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Zhang, Jihong</creatorcontrib><creatorcontrib>Gong, Ying</creatorcontrib><creatorcontrib>Peng, Juan</creatorcontrib><creatorcontrib>Han, Junling</creatorcontrib><creatorcontrib>Li, Fuqiang</creatorcontrib><creatorcontrib>Song, Liqin</creatorcontrib><creatorcontrib>Qiao, Cuifeng</creatorcontrib><title>Dose study of rosuvastatin calcium in the treatment of coronary heart disease and hyperlipidemia</title><title>American journal of translational research</title><addtitle>Am J Transl Res</addtitle><description>To study the clinical efficacy of different doses of rosuvastatin to treat elderly patients with senile coronary heart disease and hyperlipidemia. By means of retrospective analysis, 150 elderly patients with coronary heart disease and hyperlipidemia who were treated in Zhangjiakou First Hospital from January 2020 to December 2020 were selected as the study subjects. They were divided into three groups (50 patients in each group) according to the different treatment methods. All patients were given routine treatment for coronary heart disease and hyperlipidemia. At the same time, group A got 5 mg of rosuvastatin calcium per day, group B got 10 mg and group C got C, 20 mg. After 4 months of continuous treatment, changes of blood lipid level, inflammatory factors, and cardiac function in the three groups were compared before and after treatment. Finally, the incidence of adverse reactions in the three groups was statistically compared. After 4 months of treatment, the levels of TC, LDL, and TG in group B were significantly lower than those of group A, and the levels of HDL were significantly higher than those in group A (P&lt;0.05). There was no significant difference of the above indicators between groups B and C after 4 months of treatment (P&gt;0.05). Using 2 months, 3 months, and 4 months of therapy as time points, the blood lipid levels of the B and C groups was lower than in group A (P&lt;0.05); Serum hs-CRP and TNF of patients in group B and group C after 4 months of treatment were significantly lower than those of group A (P&lt;0.05); The LVEF comparison between groups showed that C was higher than A (P&lt;0.05); The occurrence rate between adverse reactions during the 4 months of medication did not have statistical significance (P&gt;0.05). Rosuvastatin calcium canimprove the clinical symptoms of elderly patients with coronary heart disease complicated by hyperlipidemia, and can improve the blood lipid level, cardiac function and the level of inflammatory factors in the body, but the clinical effect is not significantly improved by increasing the application dose. This suggests that the daily application dose should be 10 mg.</description><subject>Original</subject><issn>1943-8141</issn><issn>1943-8141</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><recordid>eNpVkEtPwzAQhCMEoqXwF5CPXCL5ETvOCaHylCpxgXPY2htqlMTBdir13xNEQeW0o93RN6M9yuasKkSuWcGOD_QsO4vxg1IlK8VPs5koBRVKyXn2dusjkphGuyO-IcHHcQsxQXI9MdAaN3ZkkmmDJAWE1GGfvo3GB99D2JENQkjEuogwgaC3ZLMbMLRucBY7B-fZSQNtxIv9XGSv93cvy8d89fzwtLxZ5QOrypQ3pcA1s5YVEioUlabAwSqjhNVYimbaallRWRa0osiYbkTDlTGFlsxothaL7PqHO4zrDq2ZegZo6yG4bqpZe3D1_0vvNvW739aMckkrpSbC1Z4Q_OeIMdWdiwbbFnr0Y6y55pLJklM-WS8Pw_5Sfv8qvgC0c3eA</recordid><startdate>20230101</startdate><enddate>20230101</enddate><creator>Zhang, Jihong</creator><creator>Gong, Ying</creator><creator>Peng, Juan</creator><creator>Han, Junling</creator><creator>Li, Fuqiang</creator><creator>Song, Liqin</creator><creator>Qiao, Cuifeng</creator><general>e-Century Publishing Corporation</general><scope>NPM</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20230101</creationdate><title>Dose study of rosuvastatin calcium in the treatment of coronary heart disease and hyperlipidemia</title><author>Zhang, Jihong ; Gong, Ying ; Peng, Juan ; Han, Junling ; Li, Fuqiang ; Song, Liqin ; Qiao, Cuifeng</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p197t-f73eb1dd145a9e3980a2ad6c63d8e73f5a98590574090e118f3f26cc4851c81b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Original</topic><toplevel>online_resources</toplevel><creatorcontrib>Zhang, Jihong</creatorcontrib><creatorcontrib>Gong, Ying</creatorcontrib><creatorcontrib>Peng, Juan</creatorcontrib><creatorcontrib>Han, Junling</creatorcontrib><creatorcontrib>Li, Fuqiang</creatorcontrib><creatorcontrib>Song, Liqin</creatorcontrib><creatorcontrib>Qiao, Cuifeng</creatorcontrib><collection>PubMed</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>American journal of translational research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Zhang, Jihong</au><au>Gong, Ying</au><au>Peng, Juan</au><au>Han, Junling</au><au>Li, Fuqiang</au><au>Song, Liqin</au><au>Qiao, Cuifeng</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Dose study of rosuvastatin calcium in the treatment of coronary heart disease and hyperlipidemia</atitle><jtitle>American journal of translational research</jtitle><addtitle>Am J Transl Res</addtitle><date>2023-01-01</date><risdate>2023</risdate><volume>15</volume><issue>5</issue><spage>3403</spage><epage>3409</epage><pages>3403-3409</pages><issn>1943-8141</issn><eissn>1943-8141</eissn><abstract>To study the clinical efficacy of different doses of rosuvastatin to treat elderly patients with senile coronary heart disease and hyperlipidemia. By means of retrospective analysis, 150 elderly patients with coronary heart disease and hyperlipidemia who were treated in Zhangjiakou First Hospital from January 2020 to December 2020 were selected as the study subjects. They were divided into three groups (50 patients in each group) according to the different treatment methods. All patients were given routine treatment for coronary heart disease and hyperlipidemia. At the same time, group A got 5 mg of rosuvastatin calcium per day, group B got 10 mg and group C got C, 20 mg. After 4 months of continuous treatment, changes of blood lipid level, inflammatory factors, and cardiac function in the three groups were compared before and after treatment. Finally, the incidence of adverse reactions in the three groups was statistically compared. After 4 months of treatment, the levels of TC, LDL, and TG in group B were significantly lower than those of group A, and the levels of HDL were significantly higher than those in group A (P&lt;0.05). There was no significant difference of the above indicators between groups B and C after 4 months of treatment (P&gt;0.05). Using 2 months, 3 months, and 4 months of therapy as time points, the blood lipid levels of the B and C groups was lower than in group A (P&lt;0.05); Serum hs-CRP and TNF of patients in group B and group C after 4 months of treatment were significantly lower than those of group A (P&lt;0.05); The LVEF comparison between groups showed that C was higher than A (P&lt;0.05); The occurrence rate between adverse reactions during the 4 months of medication did not have statistical significance (P&gt;0.05). Rosuvastatin calcium canimprove the clinical symptoms of elderly patients with coronary heart disease complicated by hyperlipidemia, and can improve the blood lipid level, cardiac function and the level of inflammatory factors in the body, but the clinical effect is not significantly improved by increasing the application dose. This suggests that the daily application dose should be 10 mg.</abstract><cop>United States</cop><pub>e-Century Publishing Corporation</pub><pmid>37303665</pmid><tpages>7</tpages></addata></record>
fulltext fulltext
identifier ISSN: 1943-8141
ispartof American journal of translational research, 2023-01, Vol.15 (5), p.3403-3409
issn 1943-8141
1943-8141
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10250966
source Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central
subjects Original
title Dose study of rosuvastatin calcium in the treatment of coronary heart disease and hyperlipidemia
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-21T20%3A02%3A39IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Dose%20study%20of%20rosuvastatin%20calcium%20in%20the%20treatment%20of%20coronary%20heart%20disease%20and%20hyperlipidemia&rft.jtitle=American%20journal%20of%20translational%20research&rft.au=Zhang,%20Jihong&rft.date=2023-01-01&rft.volume=15&rft.issue=5&rft.spage=3403&rft.epage=3409&rft.pages=3403-3409&rft.issn=1943-8141&rft.eissn=1943-8141&rft_id=info:doi/&rft_dat=%3Cproquest_pubme%3E2825157202%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2825157202&rft_id=info:pmid/37303665&rfr_iscdi=true